Skip to main content
Lotus Endometriosis Institute solid color logo
A beautiful landscape of lotus flowers

Treating Adenomyosis: From IUDs to Surgery Explained

What works for pain, heavy bleeding, and fertility—plus what to expect

Flat vector illustration of a sunlit kitchen counter seen from point-of-view, displaying assorted glass jars containing symbolic items like marbles, flowers, and hourglasses to metaphorically represent different adenomyosis treatments.

Adenomyosis is even less well understood and more under-diagnosed than endometriosis, even though there is overlap between the conditions. But because adenomyosis distributes differently in the uterus means there isn’t one “standard treatment path” that works for everyone. Some people mainly struggle with heavy bleeding and anemia. Others have severe cramping, pelvic pressure, or pain that overlaps with endometriosis. And some are trying to get pregnant—where the goal shifts from symptom control to protecting (or improving) fertility.


This article pulls together findings from multiple recent studies (including reviews, a prospective controlled study, and real-world surgical series) to map the full spectrum—from conservative, uterus-preserving options to surgery—and to explain how doctors typically determine which option(s) fits which patient.


The first question: What are you trying to treat—bleeding, pain, fertility, or all three?


Most adenomyosis treatments fall into one of three “goal categories”:

  1. Symptom-first (bleeding and/or pain): reduce heavy periods, cramps, and inflammation; improve quality of life.
  2. Fertility-first: improve the chance of implantation and live birth while keeping the uterus.
  3. Definitive treatment: end symptoms by removing the uterus (hysterectomy), when childbearing is complete or symptoms are severe.


Why does this matter? The same procedure can be a great choice for one goal and a very poor fit for another. For example, some uterus-preserving procedures are studied specifically in people who do not want future pregnancy, even though a hysterectomy essentially cures bleeding and most, if not all, of the pain. This research mis-alignment translates into what is offered to patients on a daily basis.


Hormonal treatment (including the hormonal IUD): often the starting point—especially for bleeding


Many people hear “adenomyosis” and immediately assume they need surgery. In real life, clinicians often start with hormonal suppression—especially if your main symptoms are heavy bleeding and cramping and you want to avoid major procedures.


While the studies provided here focus more on procedures and fertility-oriented care than on IUD trials specifically, they still reinforce an important theme: adenomyosis behaves like a hormonally responsive condition, and many treatment pathways—medical or procedural—work by reducing estrogen-driven activity or calming the uterine muscle and lining. The problem is that many studies suggest response to hormones is less robust than for endometriosis, which is already not great. This is at the molecular level and is based on the degree of "progestogen resistance." Progestogens are more often used for adenomyosis than estrogen reducing therapies like GnRH analogs, at least initially. Due to resistance, there may be some anti-inflammatory pain reduction but severe bleeding may persist. The results are highly individual, but a trial of each type of mormonal modulation is reasonable if uterine preservation is the goal.


What patients often like about a hormonal IUD (such as levonorgestrel IUD) in practice is that it targets bleeding from inside the uterus and can reduce cramps for many people, with a relatively low “system-wide” hormone dose. The trade-off is that it may not fully address bulk/pressure symptoms in an enlarged uterus, and it may be insufficient for severe disease.


If you’re trying to conceive now, hormonal suppression is more complicated: it can improve symptoms and may reduce inflammatory activity, but it also prevents pregnancy while you’re taking it—so timing and strategy matter.


Uterus-preserving procedures for symptom control (when you want to avoid hysterectomy)


If medication isn’t enough—or side effects are intolerable—many patients still ask: “What can I do that isn’t a hysterectomy?”


Research increasingly discusses conservative (uterus-sparing) interventions, including energy-based treatments and vascular procedures. Two key points emerge across studies:

  • These options can meaningfully improve bleeding, pain, and quality of life for selected patients. The results are largely unpredictable.
  • Some of them are best supported for people who do not plan future pregnancy (either because fertility outcomes weren’t studied or because pregnancy risks/uncertainties remain).


Focused ultrasound (HIFU/FUAS) and combining it with endometrial ablation for heavy bleeding


A prospective controlled study in women (ages 40–55) with adenomyosis, heavy bleeding, and anemia—who wanted to keep their uterus but had no future childbearing plans—found that focused ultrasound ablation improved pain, bleeding, and quality of life at 12 months. When thermal balloon endometrial ablation was added, bleeding scores and quality of life improved even more, and hemoglobin rose more as well. The trade-off was practical: longer hospitalization and longer post-procedure vaginal drainage in the combined-treatment group.


The takeaway is nuanced: if your main problem is heavy bleeding and anemia, and you are not trying to conceive, adding an endometrial ablation technique after focused ultrasound may provide extra bleeding control. But it’s not a “more is better” situation—the added procedure didn’t clearly outperform focused ultrasound alone for pain at 12 months.


Uterine artery embolization (UAE): promising symptom improvement, but fertility is a separate question


A very small 2026 case series using a novel combination of embolic materials for partial UAE reported improvements in dysmenorrhea, bleeding measures, MRI features (including uterine volume and junctional zone thickness metrics), and quality-of-life scores. Side effects were mostly short-term (pain, nausea, discharge), but one patient developed amenorrhea months later.


Importantly, that series excluded people who intended future pregnancy—yet one pregnancy occurred extremely soon after the procedure and ended in a healthy term birth. That’s a reminder that “pregnancy can happen” is not the same as “this is a fertility-optimized option.” If fertility is your goal, UAE requires especially careful counseling because the uterus and ovaries may be sensitive to changes in blood flow, and pregnancy outcome data depend heavily on technique, patient selection, and follow-up.


Fertility and adenomyosis: what treatment decisions look like when pregnancy is the goal


If you’re trying to get pregnant, the conversation changes. Adenomyosis is increasingly diagnosed in reproductive-aged patients and is repeatedly associated with lower pregnancy rates and higher miscarriage risk, particularly in assisted reproduction settings. A 2025 perspective review summarized ART-related clinical pregnancy rates around the 40–46% range in affected groups and highlighted that miscarriage/live birth outcomes can be worse than in patients without adenomyosis.


So what can be done?


Step one is often: confirm what type of adenomyosis you have


Across surgical and fertility-focused literature, one pattern is consistent: focal adenomyosis (more localized disease) tends to have better reproductive outcomes than diffuse adenomyosis (more widespread involvement). Reviews summarizing many studies repeatedly describe diffuse disease as harder to treat and more variable in outcomes.


This distinction can influence whether your team leans toward:

  • medical suppression + IVF/FET strategies,
  • uterus-sparing surgery (adenomyomectomy),
  • or non-excisional procedures.


Medical suppression before IVF/FET: sometimes longer is considered for severe disease


A case report described a patient with severe adenomyosis undergoing frozen embryo transfer with a tested (euploid) embryo. The first transfer after 3 months of suppression (GnRH agonist plus letrozole) ended in miscarriage; after 5 months of suppression (with close monitoring and intensive luteal support), the second transfer resulted in a live birth at 36 weeks.


One case cannot prove what “works,” but it illustrates a real clinical dilemma: some patients may need a more individualized, severity-based approach to suppression duration and monitoring—balanced against the burdens of prolonged low-estrogen therapy (menopausal symptoms, bone health concerns).


Find Your Best Adenomyosis Treatment

Our specialists are here to help you understand your condition and explore your treatment options.

Schedule Your Consult

Adenomyomectomy (surgery to remove adenomyosis while keeping the uterus): when is it considered?


Adenomyomectomy is usually discussed when symptoms are severe, disease is extensive but imaging can identify focal thickened areas, or fertility treatment has not succeeded—and when imaging suggests surgery is technically feasible. This means, for example, that if you structurally damage a significant part of the uterine wall, uterine rupture during pregnancy may occur.


Across a 2026 review of pregnancy after adenomyomectomy, reported clinical pregnancy rates after surgery ranged widely (about 25% to 61.5%), with miscarriage rates commonly in the teens to mid-20% range. A systematic review summarized within that paper reported a clinical pregnancy rate around 47% and a live birth rate around 36% after fertility-sparing surgery—numbers that can feel hopeful, but also underline that surgery is not a guarantee.


A separate 2025 single-center retrospective study offers a key real-world insight: the surgical and non-surgical groups weren’t comparable. In that center, non-surgical patients all had focal disease, and many conceived (most with IUI/ART), while the surgical group was mostly diffuse disease and had lower pregnancy/live birth rates overall. That doesn’t mean surgery “doesn’t work”—it more likely reflects that surgery was offered to a more severe subgroup. The same study found something clinically meaningful: after adenomyomectomy, pain scores improved strongly, and luteal-phase endometrial thickness increased, suggesting a potential mechanism by which surgery could help some patients (especially those with “thin lining” concerns).


Excision vs non-excisional uterus-sparing approaches: the evidence doesn’t clearly crown one winner


Patients often ask: “Is cutting it out better than ablating it?”


A 2025 perspective review highlighted a systematic review/meta-analysis (13 studies; 1,319 women) suggesting no statistically significant differences between excisional and non-excisional approaches in pregnancy, miscarriage, or live birth outcomes overall. That finding supports a more individualized conclusion: outcomes may depend as much on patient selection, adenomyosis type (focal vs diffuse), lesion location, imaging features (like junctional zone thickness), and local expertise as on the category of procedure itself.


The part patients deserve to hear clearly: pregnancy after adenomyomectomy can be high-risk


Even when fertility-sparing surgery helps you conceive, pregnancy management matters—because the uterine wall has been cut and reconstructed.


A 2026 review emphasized substantial obstetric risks after adenomyomectomy, especially:

  • Uterine rupture (reported across studies in the range of roughly 2.8% to 12.5%), sometimes as early as 16 weeks and not always predictable. In other words, this rupture can occur before fetal viability.
  • Placenta accreta spectrum (PAS) and related bleeding complications. This can lead to hemorrhage at delivery and emergency surgery which can lead to hysterectomy through a large incision and even death.


Real-world series illustrate both the reassurance and the caution. An older single-surgeon series of 116 diffuse adenomyosis surgeries (open adenomyomectomy with transient uterine artery occlusion) reported several pregnancies and no uterine ruptures among reported deliveries, but the numbers of pregnancies were small, and all births were by cesarean around 36 weeks on average. Meanwhile, the 2025 retrospective cohort described a case of adherent placenta/accreta requiring manual removal and uterine artery embolization, plus threatened preterm labor in others—again, small numbers, but consistent with the idea that these pregnancies merit high-alert care.


For many clinicians, this is why planned cesarean delivery is commonly recommended after adenomyomectomy, and why follow-up may include serial imaging to assess myometrial thickness and placental implantation site, with delivery planning in a center prepared for hemorrhage and possible emergency hysterectomy.


What to expect from conservative surgery for diffuse disease (symptoms + uterine preservation)


When adenomyosis is diffuse and symptoms are severe, surgery may be chosen even when fertility is uncertain—because quality of life is so impacted. However, this may lead to immediate complications, poor fertility outcomes and high risk pregnancies. So it is not a decision to undertake lightly.


In a 116-case diffuse adenomyosis series, symptom improvement at about 7 months was striking: dysmenorrhea improved in essentially all patients and heavy bleeding improved in most. But patients should also understand the “costs”: transfusions were relatively common in that cohort, reflecting that diffuse adenomyosis surgery can be a major operation with meaningful blood-loss risk (even with techniques designed to reduce it). Recurrence occurred in a minority during follow-up in this series.


Diffuse adenomyosis is like a spiderweb throughout the muscle of the uterus. In some areas, abnormal areas can be identified by feeling them as well as looking at them and then "debulked", followed by complex reconstruction with lots of suturing. The Osada Procedure is a published example and is most often performed using a laparotomy or at least. hybrid of minimally invasive technique and then a smaller laparotomy incision. This is also often a bloody procedure and placing a lot of sutures can lead to infection and loss of the uterus after a major infection. So, it can be done in a speciality center but the risks are very high with limited proof of benefit.


This is the trade-off patients often weigh: major symptom relief and uterine preservation versus invasiveness, recovery time, transfusion risk, recurrence risk, risk of death, and—if pregnancy occurs—high-risk obstetric planning, which includes the possiblity of fetal loss before viability and hysterectomy.


Practical takeaways: how to talk with your doctor about adenomyosis treatment


Use these questions to steer the appointment toward your goals and your risk tolerance:

  • “Do I have focal or diffuse adenomyosis on imaging, and how does that change my options?”
  • “Is my main issue bleeding, pain, bulk/pressure, fertility, or a mix—and which treatment best targets that?”
  • “If I’m trying to conceive: do you recommend medical suppression first, IVF/FET strategies, or discussing surgery—and why for my case?”
  • “If surgery is on the table: will you likely enter the uterine cavity? What does that mean for pregnancy risk and delivery planning?”
  • “After adenomyomectomy, how long do you recommend waiting before trying to conceive, and what monitoring will we do during pregnancy?”
  • “If I’m not trying to conceive: are options like focused ultrasound, endometrial ablation, or UAE appropriate for me—and what are the realistic benefits and downsides?”


What we still don’t know (and why your results will most likely differ from someone else’s)


Even with growing research, there are real gaps:

  • Many studies are retrospective, from single centers, and include highly selected patients—so results don’t translate perfectly to every clinic or every body.
  • Fertility outcomes can be hard to compare because groups often differ at baseline (for example, focal disease more often managed non-surgically, diffuse disease more often sent to surgery).
  • There’s no universal agreement on the “best” pre-IVF suppression duration for severe adenomyosis; individualized approaches are discussed, but robust comparative trials are limited.
  • For some newer procedural variations (like novel embolic materials for UAE), evidence is early and based on small case series.


The consistent message across the evidence is still empowering: you usually have more than one option, and the “right” choice depends on your adenomyosis type, symptom pattern, fertility goals, and your willingness to accept certain risks (especially in pregnancy after uterine surgery). Getting high-quality imaging and care from a team familiar with adenomyosis—often including minimally invasive gynecology, reproductive endocrinology, and (if pregnant after surgery) maternal-fetal medicine—can make those choices clearer and safer.

References

  1. Ioannidou, Louis, Sioutis et al.. Conservative Surgical Management of Adenomyosis: Implications for Infertility and Pregnancy Outcomes—A Perspective Review. Journal of Clinical Medicine. 2025. PMID: 41096036 PMCID: PMC12525121

  2. . Pregnancy Outcomes With and Without Adenomyomectomy in Infertile Patients With Adenomyosis: A Single‐Center Retrospective Study. The Journal of Obstetrics and Gynaecology Research. 2025. PMID: 41320195 PMCID: PMC12665454

  3. Shin, Jung, Kim et al.. Outcome of pregnancy after adenomyomectomy: a review. Obstetrics & Gynecology Science. 2026. PMID: 41261361 PMCID: PMC12862148

  4. Zhang, Li, Shi et al.. Preliminary clinical observation on the treatment of adenomyosis by partial embolization of uterine artery with novel material combination: a case series. BMC Women's Health. 2026. PMID: 41629926 PMCID: PMC12958661

  5. Yingqiang, Zhonglian, Li et al.. Synergistic Efficacy and Safety Evaluation of Focused Ultrasound Ablation Surgery Combined with Thermal Balloon Endometrial Ablation in Treating Adenomyosis: A Prospective Controlled Study. Gynecology and Minimally Invasive Therapy. 2026. PMID: 41797955 PMCID: PMC12965499

  6. . Advanced Management of Severe Adenomyosis in IVF: A Personalized Approach With Extended GnRH Agonist and Letrozole Therapy. Case Reports in Obstetrics and Gynecology. 2026. PMID: 41810057 PMCID: PMC12969224

  7. . Conservative surgery of diffuse adenomyosis with TOUA: Single surgeon experience of one hundred sixteen cases and report of fertility outcomes. The Kaohsiung Journal of Medical Sciences. 2018. PMID: 29699636 PMCID: PMC12977153

Quick Answers

What is pelvic dissection in endometriosis surgery?

Pelvic dissection in endometriosis surgery means carefully separating and opening tissue planes in the pelvis so we can clearly see normal anatomy and remove disease safely. Endometriosis can cause inflammation and scarring that “glues” organs together (sometimes called a frozen pelvis), so dissection is often the step where we free adhesions and restore normal relationships between the uterus, ovaries, bowel, bladder, and pelvic sidewalls.


In practical terms, pelvic dissection may include identifying and protecting critical structures like the ureters, bladder, bowel, blood vessels, and pelvic nerves before excising endometriosis at its roots. This is where surgical precision matters: the goal is to fully address disease while minimizing injury to healthy tissue, especially in complex or re-operative cases. If you’re seeing this term on an op note or surgical plan, it usually reflects the complexity of the anatomy and the deliberate work needed to make excision both complete and safe—our team can walk you through exactly what was dissected and why in your specific case.

Read full answer

When is menstrual bleeding considered too heavy?

Menstrual flow is generally “too heavy” when it consistently disrupts your life or overwhelms your usual period products—think flooding or soaking through pads/tampons quickly, passing frequent or large clots, needing to double up, or bleeding long enough that you can’t plan around it. Another major clue is fatigue, dizziness, or shortness of breath that can come with iron deficiency from ongoing blood loss. If you’re timing your day around bathrooms, waking at night to change products, or avoiding work, exercise, travel, or sex because of bleeding, that’s not something we consider “normal.”


Heavy bleeding is a symptom, not a diagnosis, and common underlying drivers include adenomyosis, fibroids, hormonal imbalance, and sometimes endometriosis—especially when heavy bleeding shows up with severe cramps or deep pelvic pain. Because imaging and symptoms don’t always match (a scan can look “mild” while symptoms are intense), we take a symptom-led approach and look at the full pattern, including pain, pressure, clots, cycle timing, and any signs of anemia. If your bleeding feels like it’s escalating or you’ve been told to “just live with it,” our team can help you sort out likely causes and build a plan that targets the source—not just the bleeding.

Read full answer

Can endometriosis cause arthritis-like joint pain?

Yes—endometriosis can be associated with arthritis-like joint pain in some people, even though joint pain isn’t considered a classic “core” symptom. Endometriosis can drive chronic inflammation and immune dysregulation, and that whole-body inflammatory state may show up as aching, stiffness, or flares that feel similar to inflammatory arthritis. Some patients also notice joint symptoms that cycle with their period or worsen during broader endometriosis flares.


At the same time, endometriosis doesn’t “equal” autoimmune arthritis, and an association doesn’t prove that one causes the other. Research suggests higher rates of certain autoimmune conditions in people with endometriosis—including inflammatory diseases that can affect joints—so persistent joint pain deserves a full-picture evaluation rather than being automatically attributed to pelvic disease alone. If you’re dealing with pelvic pain plus joint symptoms, our team can help you sort out what fits endometriosis, what may be a related immune condition, and how that affects your treatment plan, including whether excision surgery and coordinated integrative support make sense for you.

Read full answer

How does estrogen affect the endometrium?

Estrogen is one of the main hormones that drives endometrial growth. In the first half of the menstrual cycle, rising estrogen signals the endometrium to thicken and rebuild after a period, preparing the uterus for a possible pregnancy. It also influences the local immune and inflammatory environment in the uterus, which is part of why hormonal shifts can change bleeding patterns and pain.


When estrogen’s growth signals are strong—and progesterone’s “calming” effect is weaker than expected (often described as progesterone resistance)—the endometrium can behave in a more persistently inflamed, reactive way. This hormone–inflammation pattern is especially relevant in estrogen-dependent conditions like adenomyosis and endometriosis, where tissue similar to the endometrium can contribute to ongoing symptoms. If you’re trying to make sense of heavy bleeding, severe cramping, or cycle-linked pelvic pain, our team can help you connect the hormonal biology to what you’re feeling and review next steps for diagnosis and treatment.

Read full answer

What does a frozen uterus mean with endometriosis?

A “frozen uterus” isn’t a separate diagnosis—it’s a descriptive term surgeons use when the uterus is essentially stuck in place because endometriosis-related inflammation has caused dense scarring (adhesions). Instead of the uterus moving freely, it may be tethered to nearby structures like the bowel, bladder, ovaries, or pelvic sidewall, sometimes pulling the uterus into an abnormal position and making pelvic anatomy hard to distinguish.


This finding often suggests more advanced disease, such as deep infiltrating endometriosis and/or significant adhesions from prior inflammation or surgery, and it can help explain symptoms like deep pelvic pain, painful sex, bowel or bladder symptoms, or pain that doesn’t match what a routine exam shows. In these cases, surgery is less about “burning spots” and more about carefully restoring normal anatomy—freeing organs, protecting ureters and bowel, and removing endometriosis at its roots. If you’ve been told your uterus is “frozen,” our team can help you understand what that implies for imaging, surgical planning, and which adjacent organs may need to be evaluated as part of a complete excision strategy.

Read full answer

Reach Out

Have a question?

Dr. Steven Vasilev delivers best-in-class endometriosis guidance and a personalized treatment plan—built on evidence and your unique biology.


Led by Steven Vasilev, MD—an internationally recognized endometriosis specialist & MIGS surgeon—Lotus Endometriosis Institute is virtual-forward, with many patients traveling nationally for care. Clinical evaluation and surgical treatment are provided in California.

Santa Monica, CA

2121 Santa Monica Blvd, Santa Monica, CA 90404

Operating Hours

8:00 am - 5:00 pm
Monday - Friday

Arroyo Grande, CA

154 Traffic Way, Arroyo Grande, CA 93420